Relevant improvement has been achieved in the last 30 years in the management of patients with heart failure, with the introduction in the current guidelines 1,2 of several evidence-based treatments able to reduce the rate of occurrence of cardiovascular death and heart failure hospitalizations. As a consequence, the patients' outcomes have shown a favourable trend in the last decades. 3, 4 However, some further issues need to be tackled and solved: a) there is still the problem of misdiagnosis; 5 b) effective pharmacological or nonpharmacological treatments are available just for patients with heart failure and reduced ejection fraction (HFrEF); c) even in patients with HFrEF, adherence to the guidelines is suboptimal in terms of prescription of effective treatments but even more in terms of the use of the recommended appropriate dosage, 6, 7 with evidence that poor compliance has a significant impact on morbidity and mortality of patients treated inappropriately. 8, 9 Obviously, to address all these issues, the key element is a correct diagnosis of heart failure.
The paper of Cuthbert et al. 10 aimed to evaluate whether patients with heart failure are correctly diagnosed and then reported in registries of general practitioners and the reasons why there is potential underreporting. The analysis was performed using audit software able to identify patients with heart failure through the consideration of different features suggesting the diagnosis of heart failure. The potential overlooked cases of heart failure were then diagnostically validated by a heart failure specialist nurse.
The authors conclude that a relevant proportion of patients with heart failure are not included in the specific registries by general practitioners and that the main reason for non-inclusion is an inaccurate way of electronically coding the patients. The prevalence of heart failure was 0.63% before the audit and 1.12% after the audit, in both cases inferior to the current prevalence rates reported by epidemiological studies.
Even more interesting, the authors showed that patients treated with loop diuretics, one of the clinical variables used to identify patients with heart failure, even if the diagnosis of heart failure was not confirmed by the specialist nurse, had a poor outcome, due to a delay in the diagnosis of heart failure and to the direct negative impact of these drugs on patients' survival.
The paper has strengths and limitations. Starting with the limitations, there are no data on the type of heart failure patients, specifically if they have a reduced or a preserved ejection fraction. This information is very important due to the well known difficulties in appropriately recognizing patients with heart failure and a preserved ejection fraction. Obesity in elderly patients, more frequently of female gender, or a concomitant atrial fibrillation, can mask a correct diagnosis of heart failure. These patients are sometimes treated with loop diuretics to relieve breathing difficulties even in the absence of heart failure, with the possible negative consequences suggested by Cuthbert et al. in their paper. 10 The other limitation is the generalizability of the conclusions. The audit was conducted just in a limited area in the UK and in a relatively limited number of subjects. For this reason the messages of this manuscript cannot be automatically translated to the rest of the UK, or, even more critical, to other European or extra-European countries. In general audits are performed to improve the quality of medical activities. In this case, there is no information on the effects of the audit: was the quality of heart failure reporting improved after the audit or not? And how? With more attention in coding the patients? Or with the introduction in practice of more diagnostic tests such as the measure of natriuretic peptides or a larger use of echocardiographic or other imaging examinations? All these data are obviously relevant if this audit system has to be recommended in a more extensive way.
It must be recognized that the findings of Cuthbert et al. provide some important contributions. The first consideration is that, when a structured system of registering patients' diagnoses by general practitioners is overseen by a local or national health organization, it is possible to evaluate the appropriateness of patients' management, to improve the quality of care, and if it appears not sufficiently accurate, to plan programmes of education/intervention aimed at correcting the potential shortcomings. The UK area that was the subject of this study not only has a coding system fully integrated into the usual clinical practice activities, but it is also possible to perform regular audits, even testing different systems of evaluation, in this case a software-based system followed by a confirmation by specialist nurses. In how many countries of Europe has a system such as that described by the work of Cuthbert et al. been implemented? How is it possible to check, in real practice, the quality of diagnoses and improve the patients' management without systems like that? The use of electronic systems of data collection is easier today than in the past. Their widespread implementation should be encouraged to improve the possibility to create real-life epidemiological data, to periodically evaluate the quality of the activities of health professionals, to plan educational programmes aimed at correcting potential inaccuracies and, as a logical consequence, to improve patients' outcomes.
The other critical contribution of the paper is the observation related to the use of loop diuretics in patients in whom heart failure was not yet present. These patients should be considered at high risk (a) of masking a future diagnosis of heart failure and (b) of a poor outcome. The use of loop diuretics in patients who do not have a clear indication, such as the presence of pulmonary or peripheral congestion, should be carefully considered in clinical practice due to the risks that their use may entail.
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